ENUreteral cancer treatment in Germany depends on risk: removing the kidney and ureter for high-risk tumours, keeping the kidney where possible for small low-risk ones, and drugs first for spread disease. It grows from the same lining as bladder cancer, inside the thin tube from kidney to bladder. It is rare and often found late. Guidelines group it with renal pelvis tumours as upper tract urothelial cancer.
Below: diagnosis, why the kidney decision precedes surgery, advanced disease, and the records a German department needs.
What this tumour is and why it is hard to catch
It is a urothelial cancer, hard to catch because early on there may be no symptoms. The ureter is a thin-walled tube about 25 cm long, and tumours here have reached the muscle layer at diagnosis far more often than bladder tumours. Blood in the urine, often painless, is the commonest sign; flank pain from blocked flow is rarer.
Many arrive with a real but incomplete diagnosis: ultrasound and plain CT show a swollen kidney above a blockage but not always its cause — tumour, stone or clot.
The full workup includes CT urography, a contrast CT timed to the filling of the urinary tract; urine cytology for tumour cells; cystoscopy, a look inside the bladder. If needed, ureteroscopy follows: a thin endoscope inspects the ureter and takes a biopsy. High-risk tumours add a chest CT to rule out distant spread. This follows the European Association of Urology guidelines; see also Urology in Germany.
Surgery: when the kidney goes and when it stays
The kidney goes when the tumour is high-risk: the standard is nephroureterectomy, removing the kidney, the whole ureter and a cuff of bladder wall around its opening. No stump is left, as recurrence there and in the bladder is a considerable risk, and everything comes out in one piece, the urinary tract unopened, so no tumour cells spill. Open, laparoscopic and robotic operations give broadly similar cancer outcomes.
For a small low-risk tumour, European guidelines make keeping the kidney the primary option. With high risk it is reserved for a single kidney, disease on both sides or poor function. The tumour is lasered through the ureteroscope or the affected segment cut out and the ureter rejoined; drug instillation into the renal pelvis is of unproven benefit. Keeping the organ means closer surveillance, not lighter treatment. A similar choice arises in kidney cancer.
The tumour board weighs biopsy, cytology, tumour size and site, and the other kidney’s function. Among AlenMed’s partners, the urology department of Katholisches Marienkrankenhaus in Hamburg is headed by Professor Michael Rink, who works in uro-oncological surgery including the ureter, robot-assisted laparoscopic surgery and endoscopic urinary tract surgery. At the Urology Clinic Munich-Planegg, head physician and clinic director Professor Maximilian Kriegmair operates with the da Vinci robot and performs ureteral and urethral reconstruction. More departments: Urology clinics in Germany.
What is done in advanced disease
Spread disease is treated first with drugs acting throughout the body, not surgery. They are those used for bladder cancer, covered in German by the Krebsinformationsdienst of the German Cancer Research Center. First choice in European guidelines is enfortumab vedotin with the immunotherapy drug pembrolizumab, EU-approved for first-line use. Enfortumab vedotin is a conjugate, an antibody that carries a drug into the tumour cell. Otherwise platinum-based chemotherapy is given, then maintenance immunotherapy if the disease does not progress. With FGFR3 gene alterations, erdafitinib tablets are an option after immunotherapy.
For a locally advanced tumour, drugs sometimes come before surgery: cisplatin needs good kidney function, and after the operation the remaining kidney may no longer provide it. So a German department may be in no hurry to operate. This approach lacks randomised trials; better studied is platinum-based chemotherapy after surgery, advised once the tumour has reached the muscle layer or lymph nodes.
In practice, stage 4 means spread into a neighbouring organ, the lymph nodes or distant sites; with nearby lymph nodes, surgery may follow a drug response. With distant metastases the aim is to hold the disease back and ease symptoms; procedures address a blocked kidney, with a stent or nephrostomy drain, or bleeding.
Follow-up after treatment
Follow-up is close because the urothelium tends to form new tumours elsewhere, including the bladder. After nephroureterectomy, patients without previous bladder cancer get one dose of chemotherapy into the bladder, then cystoscopy, urine cytology and CT urography on the department’s schedule, plus chest CT at high risk.
Patients from abroad can do part of it at home if the discharge letter sets out the protocol in a language their doctor reads: ask for the surveillance plan, not just the report.
What to collect before making contact
Collect everything about the tumour and kidneys: discharge letters, histology and cytology with blocks or slides, CT urography and chest CT discs, the ureteroscopy report, blood tests with creatinine and estimated kidney function, other illnesses and medication.
The order: written assessment, consultation in person, plan. Without kidney function data no tumour board can say which operation and chemotherapy are possible. An existing plan can be checked with a second opinion from a German doctor.
Frequently asked questions
Does the kidney always have to be removed in ureteral cancer?
No. For a small low-risk tumour, keeping the kidney is the primary option. With high risk, removal is standard, but kidney-sparing surgery is considered for a single kidney, disease on both sides or poor function. Keeping the kidney always means close surveillance.
Can ureteral cancer be cured?
That depends on the stage. Without distant metastases, treatment aims at cure: surgery, with chemotherapy where indicated. With distant metastases the aim is usually to hold the disease back and relieve symptoms. Only a doctor who has seen the histology and scans can give a prognosis.
Is ureteral cancer hereditary?
Usually not, but it can be part of Lynch syndrome, an inherited tendency to bowel, womb-lining and upper urinary tract cancers, so doctors ask about cancer in the family and suggest genetic testing when it is suspected. Smoking and aristolochic acid from some herbal remedies are established causes.
How AlenMed organises treatment
A medical interpreter translates the records for two or three urology departments; each replies whether it accepts the patient, what it proposes and in what order. Medical visa paperwork runs alongside.
AlenMed has 86 partner hospitals in 38 cities, 345 doctors and an office in Munich. A coordinator books appointments, interprets, handles logistics between visits and collects the discharge letter with the follow-up plan.
This material is for information only and is not an offer; treatment is decided by a doctor in person.
News on this topic
Charité treats first beta-thalassemia patient with CRISPR
At Berlin Charité, a 19-year-old beta-thalassemia patient became the first in Germany to receive the newly approved CRISPR gene therapy Exagamglogene Autotemcel.
Real-World Breast Cancer Study Confirms High Five-Year Survival Rates in Germany
A landmark study of over 43,000 German patients reveals a five-year invasive disease-free survival rate of 82.9 percent in early hormone receptor-positive breast cancer.
FDA Approves Jülich Diagnostic Radiotracer FET for Brain Tumor Imaging
The FDA approves the diagnostic radiotracer FET (Pixclara®) for evaluating brain gliomas, highlighting decades of neuro-oncology research at Forschungszentrum Jülich.
